organization · Reporting owner
Versant Voyageurs I Parallel, L.P.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | 10% owner | August 28, 2024 | August 30, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Black Diamond Therapeutics, Inc.
Report date August 28, 2024 · Filed August 30, 2024
Jointly reported with Versant Venture Capital VI, L.P., Versant Voyageurs I, L.P., Versant Vantage I, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,726,341 |
Reported balance
After 2024-08-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-08-28 · Sale · Disposed 221,600 · Balance 3,726,341 F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.32 to $6.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2: These shares are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,277,541 |
Reported balance
Holding disclosure · report date 2024-08-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,277,541 F3: These shares are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company ("Versant Voyageurs I GP") is the general partner of Versant Voyageurs I and may be deemed to share voting, investment and dispositive power over the shares held by Versant Voyageurs I. Versant Voyageurs I GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 380,942 |
Reported balance
Holding disclosure · report date 2024-08-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 380,942 F4: These shares are held of record by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP LP") is the general partner of Versant I Parallel and may be deemed to share voting, investment and dispositive power over the shares held by Versant I Parallel and disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 822,140 |
Reported balance
Holding disclosure · report date 2024-08-28 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 822,140 F5: These shares are held of record by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP and each may be deemed to share voting, investment and dispositive power over the shares held by Versant Vantage I. Each of Versant Vantage I GP-GP and Versant Vantage I GP LP disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.32 to $6.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2: These shares are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
F3: These shares are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company ("Versant Voyageurs I GP") is the general partner of Versant Voyageurs I and may be deemed to share voting, investment and dispositive power over the shares held by Versant Voyageurs I. Versant Voyageurs I GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interests therein.
F4: These shares are held of record by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP LP") is the general partner of Versant I Parallel and may be deemed to share voting, investment and dispositive power over the shares held by Versant I Parallel and disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein.
F5: These shares are held of record by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP and each may be deemed to share voting, investment and dispositive power over the shares held by Versant Vantage I. Each of Versant Vantage I GP-GP and Versant Vantage I GP LP disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CHINOOK THERAPEUTICS, INC.
Report date April 04, 2022 · Filed April 06, 2022
Jointly reported with Versant Venture Capital VII, L.P., Versant Voyageurs I, L.P.
Section 16 reporting ended · disclosed 2022-04-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,913,070 |
Reported balance
After 2022-04-04 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-04-04 · Other · Disposed 709,953 · Balance 2,913,070 F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VII, L.P. ("Versant VII") to its partners pursuant to a Rule 10b5-1 trading plan. F2: These securities are held of record by Versant VII. Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Versant Ventures VII GP-GP, Versant Ventures VII GP and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 14,194 |
Reported balance
After 2022-04-04 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2022-04-04 · Other · Acquired 14,194 · Balance 14,194 F3: Represents a change in the form of ownership of Versant Ventures VII GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant VII. F4: Shares held by Versant Ventures VII GP. Versant Ventures VII GP-GP is the general partner of Versant Ventures VII GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP. Each of Versant Ventures VII GP-GP and Jerel C. Davis disclaim beneficial ownership of the shares held by Versant Ventures VII GP, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2022-04-04 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2022-04-04 · Other · Disposed 14,194 · Balance 0 F5: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VII GP to its partners. F4: Shares held by Versant Ventures VII GP. Versant Ventures VII GP-GP is the general partner of Versant Ventures VII GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP. Each of Versant Ventures VII GP-GP and Jerel C. Davis disclaim beneficial ownership of the shares held by Versant Ventures VII GP, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 11,726 |
Reported balance
After 2022-04-04 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2022-04-04 · Other · Acquired 11,726 · Balance 11,726 F6: Represents a change in the form of ownership of Versant Ventures VII GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VII GP. F7: Shares held by Versant Ventures VII GP-GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP-GP. Jerel C. Davis disclaims beneficial ownership of the shares held by Versant Ventures VII GP-GP, except to the extent of his pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2022-04-04 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2022-04-04 · Other · Disposed 11,726 · Balance 0 F8: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VII GP-GP to its members. F7: Shares held by Versant Ventures VII GP-GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP-GP. Jerel C. Davis disclaims beneficial ownership of the shares held by Versant Ventures VII GP-GP, except to the extent of his pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,863,197 |
Reported balance
Holding disclosure · report date 2022-04-04 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 1,863,197 F9: These securities are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. Jerel C. Davis, a member of the Issuer's board of directors, is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Versant Voyageurs I GP Company and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 552,149 |
Reported balance
Holding disclosure · report date 2022-04-04 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 552,149 F10: These securities are held of record by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP, Versant Voyageurs I GP and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VII, L.P. ("Versant VII") to its partners pursuant to a Rule 10b5-1 trading plan.
F2: These securities are held of record by Versant VII. Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Versant Ventures VII GP-GP, Versant Ventures VII GP and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.
F3: Represents a change in the form of ownership of Versant Ventures VII GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant VII.
F4: Shares held by Versant Ventures VII GP. Versant Ventures VII GP-GP is the general partner of Versant Ventures VII GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP. Each of Versant Ventures VII GP-GP and Jerel C. Davis disclaim beneficial ownership of the shares held by Versant Ventures VII GP, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.
F5: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VII GP to its partners.
F6: Represents a change in the form of ownership of Versant Ventures VII GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VII GP.
F7: Shares held by Versant Ventures VII GP-GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP-GP. Jerel C. Davis disclaims beneficial ownership of the shares held by Versant Ventures VII GP-GP, except to the extent of his pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.
F8: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VII GP-GP to its members.
F9: These securities are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. Jerel C. Davis, a member of the Issuer's board of directors, is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Versant Voyageurs I GP Company and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.
F10: These securities are held of record by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP, Versant Voyageurs I GP and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 28, 2024 Filed Aug 30, 2024 16:16 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 221,600 | $6.32 | $1,400,556.32 |
DisclosureSEC source: 0000950170-24-102354 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,726,341 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.32 to $6.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.direct: These shares are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 16:38 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | OtherCommon Stock | 11,726 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-014108 · doc4.xml · nonDerivative · entry 5 Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F8 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VII GP-GP to its members. F7 · ownership.nature: Shares held by Versant Ventures VII GP-GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP-GP. Jerel C. Davis disclaims beneficial ownership of the shares held by Versant Ventures VII GP-GP, except to the extent of his pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 16:38 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | OtherCommon Stock | 11,726 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-014108 · doc4.xml · nonDerivative · entry 4 Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 11,726 F6 · kind: Represents a change in the form of ownership of Versant Ventures VII GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VII GP. F7 · ownership.nature: Shares held by Versant Ventures VII GP-GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP-GP. Jerel C. Davis disclaims beneficial ownership of the shares held by Versant Ventures VII GP-GP, except to the extent of his pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 16:38 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | OtherCommon Stock | 14,194 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-014108 · doc4.xml · nonDerivative · entry 3 Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VII GP to its partners. F4 · ownership.nature: Shares held by Versant Ventures VII GP. Versant Ventures VII GP-GP is the general partner of Versant Ventures VII GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP. Each of Versant Ventures VII GP-GP and Jerel C. Davis disclaim beneficial ownership of the shares held by Versant Ventures VII GP, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 16:38 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | OtherCommon Stock | 14,194 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-014108 · doc4.xml · nonDerivative · entry 2 Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 14,194 F3 · kind: Represents a change in the form of ownership of Versant Ventures VII GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant VII. F4 · ownership.nature: Shares held by Versant Ventures VII GP. Versant Ventures VII GP-GP is the general partner of Versant Ventures VII GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP. Each of Versant Ventures VII GP-GP and Jerel C. Davis disclaim beneficial ownership of the shares held by Versant Ventures VII GP, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 16:38 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | OtherCommon Stock | 709,953 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-014108 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,913,070 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VII, L.P. ("Versant VII") to its partners pursuant to a Rule 10b5-1 trading plan. F2 · ownership.direct: These securities are held of record by Versant VII. Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Versant Ventures VII GP-GP, Versant Ventures VII GP and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 17:16 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 92,000 | $16.00 | $1,472,018.40 |
DisclosureSEC source: 0000899243-22-000946 · doc4.xml · nonDerivative · entry 3 Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 552,149 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Venture Capital VII, L.P. ("Versant VII"), Versant Voyageurs I, L.P. ("Versant Voyageurs I") and Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F5 · ownership.nature: These securities are held of record by Versant I Parallel. Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP, Versant Voyageurs I GP and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 17:16 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 308,000 | $16.00 | $4,928,061.60 |
DisclosureSEC source: 0000899243-22-000946 · doc4.xml · nonDerivative · entry 2 Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,863,197 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Venture Capital VII, L.P. ("Versant VII"), Versant Voyageurs I, L.P. ("Versant Voyageurs I") and Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F4 · ownership.nature: These securities are held of record by Versant Voyageurs I. Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. Jerel C. Davis, a member of the Issuer's board of directors, is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Versant Voyageurs I GP Company and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 17:16 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 600,000 | $16.00 | $9,600,120.00 |
DisclosureSEC source: 0000899243-22-000946 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,623,023 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Venture Capital VII, L.P. ("Versant VII"), Versant Voyageurs I, L.P. ("Versant Voyageurs I") and Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · ownership.direct: These securities are held of record by Versant VII. Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Versant VII GP-GP, Versant VII GP and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 19:06 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 78,098 | $14.00 | $1,093,372.00 |
DisclosureSEC source: 0000899243-21-034627 · doc4.xml · nonDerivative · entry 3 Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 644,149 F3 · ownership.nature: These securities are held of record by Versant Voyageurs I Parallel L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP, Versant Voyageurs I GP and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 19:06 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 261,902 | $14.00 | $3,666,628.00 |
DisclosureSEC source: 0000899243-21-034627 · doc4.xml · nonDerivative · entry 2 Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,171,197 F2 · ownership.nature: These securities are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. Jerel C. Davis, a member of the Issuer's board of directors, is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Versant Voyageurs I GP Company and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 19:06 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 510,000 | $14.00 | $7,140,000.00 |
DisclosureSEC source: 0000899243-21-034627 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,223,023 F1 · ownership.direct: These securities are held of record by Versant Venture Capital VII, L.P. ("Versant VII"). Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Versant VII GP-GP, Versant VII GP and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 19:04 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 307 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-034179 · doc4.xml · nonDerivative · entry 5 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F8 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I GP-GP, to its members. F7 · ownership.nature: Shares held by Versant Vantage I GP-GP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held Versant Vantage I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 19:04 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 307 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-034179 · doc4.xml · nonDerivative · entry 4 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 307 F6 · kind: Represents a change in the form of ownership of Versant Vantage I GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I GP LP. F7 · ownership.nature: Shares held by Versant Vantage I GP-GP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held Versant Vantage I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 19:04 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 310 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-034179 · doc4.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I GP LP, to its partners. F4 · ownership.nature: Shares held by Versant Vantage I GP LP. Versant Vantage I GP-GP is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 19:04 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 310 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-034179 · doc4.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 310 F3 · kind: Represents a change in the form of ownership of Versant Vantage I GP LP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I. F4 · ownership.nature: Shares held by Versant Vantage I GP LP. Versant Vantage I GP-GP is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 19:04 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 20,784 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-034179 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 822,140 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I, L.P. ("Versant Vantage I"), to its partners, pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 30, 2020 Filed Dec 1, 2020 19:13 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 463 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032389 · doc4.xml · nonDerivative · entry 12 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F19 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I GP-GP, to its members. F18 · ownership.nature: Shares held by Versant Vantage I GP-GP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held Versant Vantage I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 30, 2020 Filed Dec 1, 2020 19:13 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 463 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032389 · doc4.xml · nonDerivative · entry 11 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 463 F17 · kind: Represents a change in the form of ownership of Versant Vantage I GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I GP LP. F18 · ownership.nature: Shares held by Versant Vantage I GP-GP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held Versant Vantage I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 30, 2020 Filed Dec 1, 2020 19:13 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 467 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032389 · doc4.xml · nonDerivative · entry 10 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F16 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I GP LP, to its partners. F15 · ownership.nature: Shares held by Versant Vantage I GP LP. Versant Vantage I GP-GP is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 30, 2020 Filed Dec 1, 2020 19:13 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 467 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032389 · doc4.xml · nonDerivative · entry 9 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 467 F14 · kind: Represents a change in the form of ownership of Versant Vantage I GP LP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I. F15 · ownership.nature: Shares held by Versant Vantage I GP LP. Versant Vantage I GP-GP is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 30, 2020 Filed Dec 1, 2020 19:13 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 31,175 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032389 · doc4.xml · nonDerivative · entry 8 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 842,924 F13 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I to its partners, pursuant to a Rule 10b5-1 trading plan. F11 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 30, 2020 Filed Dec 1, 2020 19:13 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 200 | $34.16 | $6,832.92 |
DisclosureSEC source: 0000899243-20-032389 · doc4.xml · nonDerivative · entry 7 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 874,099 F9 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Vantage I, L.P. ("Versant Vantage I"). F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.77 to $34.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (12) to this Form 4. F11 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 30, 2020 Filed Dec 1, 2020 19:13 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 10,193 | $33.13 | $337,679.82 |
DisclosureSEC source: 0000899243-20-032389 · doc4.xml · nonDerivative · entry 6 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 874,299 F9 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Vantage I, L.P. ("Versant Vantage I"). F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (10) to this Form 4. F11 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 27, 2020 Filed Dec 1, 2020 19:13 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 6,797 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032389 · doc4.xml · nonDerivative · entry 5 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F8 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VI GP-GP to its members. F7 · ownership.nature: Shares held by Versant Ventures VI GP-GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VI GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 27, 2020 Filed Dec 1, 2020 19:13 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 6,797 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032389 · doc4.xml · nonDerivative · entry 4 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,797 F6 · kind: Represents a change in the form of ownership of Versant Ventures VI GP-GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VI GP. F7 · ownership.nature: Shares held by Versant Ventures VI GP-GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VI GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 27, 2020 Filed Dec 1, 2020 19:13 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 7,880 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032389 · doc4.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VI GP to its partners. F4 · ownership.nature: Shares held by Versant Ventures VI GP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VI GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 27, 2020 Filed Dec 1, 2020 19:13 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 7,880 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032389 · doc4.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,880 F3 · kind: Represents a change in the form of ownership of Versant Ventures VI GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant VI. F4 · ownership.nature: Shares held by Versant Ventures VI GP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VI GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 27, 2020 Filed Dec 1, 2020 19:13 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 394,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032389 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,947,941 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VI, L.P. ("Versant VI") to its partners. F2 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 16:49 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 3,316 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032169 · doc4.xml · nonDerivative · entry 15 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F24 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I GP LP, to its partners. F20 · ownership.nature: Shares held by Versant Voyageurs I GP LP. Bradley J. Bolzon is a partner of Versant Voyageurs I GP LP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 16:49 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 2,488 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032169 · doc4.xml · nonDerivative · entry 14 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,316 F23 · kind: Represents a change in the form of ownership of Versant Voyageurs I GP LP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant I Parallel. F20 · ownership.nature: Shares held by Versant Voyageurs I GP LP. Bradley J. Bolzon is a partner of Versant Voyageurs I GP LP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 16:49 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 46,121 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032169 · doc4.xml · nonDerivative · entry 13 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 380,942 F21 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel") to its partners. F22 · ownership.nature: Shares held by Versant I Parallel. Versant Voyageurs I GP LP is the general partner of Versant I Parallel. Versant Ventures VI GP is the general partner of Versant Voyageurs I GP LP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 16:49 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 828 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032169 · doc4.xml · nonDerivative · entry 12 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 828 F19 · kind: Represents a change in the form of ownership of Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP LP") by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Voyageurs I. F20 · ownership.nature: Shares held by Versant Voyageurs I GP LP. Bradley J. Bolzon is a partner of Versant Voyageurs I GP LP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 16:49 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 154,671 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032169 · doc4.xml · nonDerivative · entry 11 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,277,541 F17 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I, L.P. ("Versant Voyageurs I") to its partners. F18 · ownership.nature: Shares held by Versant Voyageurs I. Versant Voyageurs I GP Company ("Versant Voyageurs I GP") is the general partner of Versant Voyageurs I. Bradley J. Bolzon may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 16:49 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 1,258 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032169 · doc4.xml · nonDerivative · entry 10 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F16 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I GP-GP, to its members. F15 · ownership.nature: Shares held by Versant Vantage I GP-GP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held Versant Vantage I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 16:49 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 1,258 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032169 · doc4.xml · nonDerivative · entry 9 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,258 F14 · kind: Represents a change in the form of ownership of Versant Vantage I GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I GP LP. F15 · ownership.nature: Shares held by Versant Vantage I GP-GP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held Versant Vantage I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 16:49 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 1,269 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032169 · doc4.xml · nonDerivative · entry 8 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F13 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I GP LP, to its partners. F12 · ownership.nature: Shares held by Versant Vantage I GP LP. Versant Vantage I GP-GP is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 16:49 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 1,269 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032169 · doc4.xml · nonDerivative · entry 7 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,269 F11 · kind: Represents a change in the form of ownership of Versant Vantage I GP LP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I. F12 · ownership.nature: Shares held by Versant Vantage I GP LP. Versant Vantage I GP-GP is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 16:49 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 84,462 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032169 · doc4.xml · nonDerivative · entry 6 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 884,492 F9 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I, L.P. ("Versant Vantage I") to its partners. F10 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 16:49 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 8,223 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032169 · doc4.xml · nonDerivative · entry 5 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F8 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VI GP-GP to its members. F7 · ownership.nature: Shares held by Versant Ventures VI GP-GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VI GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 16:49 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 8,223 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032169 · doc4.xml · nonDerivative · entry 4 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,223 F6 · kind: Represents a change in the form of ownership of Versant Ventures VI GP-GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VI GP. F7 · ownership.nature: Shares held by Versant Ventures VI GP-GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VI GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 16:49 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 9,533 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032169 · doc4.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VI GP to its partners. F4 · ownership.nature: Shares held by Versant Ventures VI GP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VI GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 16:49 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 9,533 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032169 · doc4.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,533 F3 · kind: Represents a change in the form of ownership of Versant Ventures VI GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant VI. F4 · ownership.nature: Shares held by Versant Ventures VI GP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VI GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 16:49 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 476,659 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032169 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,341,941 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VI, L.P. ("Versant VI") to its partners. F2 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 16:41 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 114,854 | $33.01 | $3,791,330.54 |
DisclosureSEC source: 0000899243-20-031918 · doc4.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,818,600 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F4 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 16:41 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 15,163 | $33.01 | $500,530.63 |
DisclosureSEC source: 0000899243-20-031918 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 968,954 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 18, 2020 Filed Nov 19, 2020 21:19 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 473 | $33.09 | $15,653.37 |
DisclosureSEC source: 0000899243-20-031771 · doc4.xml · nonDerivative · entry 4 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,933,454 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.025 to $33.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F4 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 18, 2020 Filed Nov 19, 2020 21:19 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 63 | $33.09 | $2,084.91 |
DisclosureSEC source: 0000899243-20-031771 · doc4.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 984,117 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.025 to $33.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 21:19 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 3,705 | $33.05 | $122,449.51 |
DisclosureSEC source: 0000899243-20-031771 · doc4.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,933,927 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F4 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Bradley J. Bolzon is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 21:19 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 489 | $33.05 | $16,161.35 |
DisclosureSEC source: 0000899243-20-031771 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Voyageurs I Parallel, L.P. · CIK 0001745961 · 10% owner Versant Voyageurs I, L.P. · CIK 0001745960 · 10% owner Versant Vantage I, L.P. · CIK 0001765253 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 984,180 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"), respectively. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. Bradley J. Bolzon is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Bradley J. Bolzon is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.